Clinical trials: Neurocognitive Deficit
- Condition Neurocognitive Deficit
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Multiple Sclerosis, Cognitive Impairment
Rivastigmine in Multiple Sclerosis Patients With Cognitive Impairment
This study evaluated the efficacy and safety of 10 cm² rivastigmine patch vs. placebo in cognitively impaired Multiple Sclerosis (MS) patients.
- Trial name
- EXCITING (NCT00881205)
- Testing
- Rivastigmine transdermal patch
- Where
- 49 sites in Germany
- Volunteers
- 86 people
- Sponsor
- Novartis Pharmaceuticals
Memory Impairment, Alzheimer's Disease
Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy Adults
The purpose of this study is to determine whether scopolamine-induced cognitive impairment is attenuated by the administration of roflumilast in combination with donepezil.
- Trial name
- NCT02051335
- Testing
- Roflumilast, Donepezil, Scopolamine
- Where
- United Kingdom
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- AstraZeneca